Disruptive Pharma sells GTX platform to Aurelia Invest unit
Disruptive Pharma has agreed to sell its GTX platform, including peptide programs and lead candidate GTX-86, to a wholly owned subsidiary of Aurelia Invest. The deal includes a modest upfront cash payment, with Disruptive Pharma retaining royalties, future milestone payments, and a share of proceeds from any future sal